Do thiazolidinediones cause heart failure? A critical review
W.H. Wilson Tang, MD
Section of Heart Failure and Cardiac Transplantation, Department of Cardiovascular Medicine, Cleveland Clinic
Address: W.H. Wilson Tang, MD, Department of Cardiovascular Medicine, F25, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail firstname.lastname@example.org
Dr. Tang has indicated that he previously served as a consultant for GlaxoSmithKline Pharmaceuticals, Amylin Pharmaceuticals, and F. Hoffmann-La Roche Ltd. He is a member of the speakers’ bureau for Takeda Pharmaceuticals.
ABSTRACTConcern has been raised about whether the fluid retention caused by thiazolidinediones (TZDs, ie, rosiglitazone and pioglitazone) can cause or exacerbate congestive heart failure. Although fluid retention is a worrisome side effect of TZDs, current evidence does not link fluid retention caused by TZDs with worsening heart function. TZDs have many benefits for patients with diabetes and can even be used cautiously in patients with mild heart failure, with careful monitoring of volume status.